Compare JetBlue Airways Corporation (JBLU) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs 10X Genomics Inc — how do they compare? JetBlue Airways Corporation trades at $5.34 (market cap $2.03B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: 10X Genomics Inc is far larger — about 2.7× JetBlue Airways Corporation's market cap, and 10X Genomics Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| JBLU | TXG | |
|---|---|---|
Market Cap | $2.03B | $5.48B |
Sector | Industrials | Health |
52-Week High | $6.46 | $45.80 |
52-Week Low | $4.03 | $11.34 |
Enterprise Value | $9.19B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.35, down 1.29% on the day, with mixed technical signals showing a neutral overall bias. The company faces fundamental challenges with negative profitability metrics, including a -7.78% net income margin and -33.51% ROE, despite reasonable valuation ratios like P/S of 0.22. Recent developments include securing Spirit Airlines' LaGuardia Airport slots and launching new payment partnerships, providing potential operational catalysts amid ongoing losses.
The outlook remains challenging with persistent net losses and high debt levels, though strategic expansions and new financing options offer growth potential. Key risks include fuel cost volatility and competitive pressures, while analyst sentiment is cautious with a $5.12 consensus target suggesting limited upside from current levels.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
